GLPwatch
Lixisenatide vs Pemvidutide
Molecule comparison
Last updated 2026-05-28 15:46 UTCLixisenatide (brand names Adlyxin and Soliqua) is an FDA-approved GLP-1 receptor agonist used to treat type 2 diabetes, taken as an injection. Pemvidutide, still in development, is a dual GLP-1 and glucagon receptor agonist that has not yet been approved for any treatment.
AI summary of the sources below.
| Lixisenatide | Pemvidutide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 and glucagon receptor dual agonist |
| Status | Approved | Pipeline |
| Branded products | adlyxin, soliqua | — |
Compare full details on the Lixisenatide and Pemvidutide pages.